Objective
The aim of the present study was to evaluate the anticancer effects of Moringa oleifera fruit extracts and their bioactive polyphenols, specifically quercetin and kaempferol, against colorectal cancer cell lines, and to validate their molecular interactions with relevant target proteins through in silico and in vitro approaches.
Materials and methods
Preliminary phytochemical screening and GC-MS analysis were conducted to identify the phytochemical composition of Moringa oleifera. Anticancer activity was evaluated using MTT assay against HCT-116 colorectal cancer cells, microscopy, and AO/EtBr staining. Additionally, molecular docking, ADMET analysis, and molecular dynamics (MD) simulations were performed to assess the binding affinity and stability of major phytoconstituents against BRAF V600E—a mutation in the BRAF gene implicated in colorectal cancer.
Results
The hydroalcoholic fruit extract confirmed the presence of key secondary metabolites. GC-MS identified 26 bioactive compounds, with (E)-9-Octadecenoic acid ethyl ester and cis-Vaccenic acid in high quantities. The extract showed concentration-dependent cytotoxicity in MTT assays against HCT-116 colorectal cancer cells, with an IC₅₀ of 13.076 ± 3.288 µg/ml. Apoptotic effects were evident through AO/EtBr staining and phase-contrast microscopy, with outcomes comparable to Paclitaxel. In silico, 10 major phytoconstituents were docked with BRAF V600E kinase (PDB ID: 6XFP), an oncogenic target in colorectal cancer. Quercetin and Kaempferol showed stronger binding affinities (-11.1685 and −10.4259 kcal/mol) than Encorafenib (-10.0141 kcal/mol). MD simulations confirmed the stability of the Quercetin–BRAF complex, while Kaempferol showed lower stability.
Conclusions
This is the first report on the anticancer effects of Moringa oleifera fruit extract against colorectal cancer via BRAF targeting. Quercetin emerged as a promising natural BRAF inhibitor, meriting further in vivo validation.
扫码关注我们
求助内容:
应助结果提醒方式:
